Home
Drugs
Docetaxel

Docetaxel

Drug

Drug Profile

Docetaxel is a taxane chemotherapy medicine used for multiple cancers including breast, head and neck, stomach, prostate, and non-small-cell lung cancer. It is administered by slow IV infusion and may be used alone or in combination regimens. It is a prescription-only antineoplastic drug.

Drug Class: Taxane chemotherapy
Approval Status: Approved for medical use in 1995; prescription-only in major markets
Mechanism of Action: Disrupts normal microtubule function and thereby blocks cell division

Brand Names

Taxotere
Docecad
Docefrez

Indications

\Breast cancer\
\Head and neck cancer\
\Stomach cancer\
\Prostate cancer\
\Non-small-cell lung cancer\

Related News

High Biomarker Testing Rates Achieved Across Racial Groups in Metastatic Triple-Negative Breast Cancer, Yet Disparities Persist

Aug 03, 2026

A study of 450 mTNBC patients in community practices found high biomarker testing rates and encouraging outcomes across racial groups, with Hispanic patients showing the longest survival. However, Black women of West African ancestry face the highest TNBC incidence and greater neuropathy from paclitaxel, making docetaxel a potential alternative. Social determinants like neighborhood deprivation and allostatic load are also linked to TNBC risk.

New Studies Reveal How Cancer Cells Survive Chemotherapy and Resist Treatment

Jul 31, 2026

New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.

Candel Initiates Phase 3 AURORA Trial, Advances Aglatimagene Toward BLA and Launch

Jul 29, 2026

Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.

Ferroptosis and Cuproptosis Emerge as Key Cancer Therapy Targets in New Studies

Jul 08, 2026

Studies highlight ferroptosis and cuproptosis in cancer therapy: a DDR1/VEGFR2 inhibitor reverses gastric cancer chemoresistance, GSH-responsive nanoparticles enhance HCC immunotherapy, and nutrient restriction boosts Sorafenib-induced ferroptosis.

Telix Gains FDA Alignment to Advance ProstACT Global Phase 3 Trial in U.S.

Jul 02, 2026

Telix gained FDA alignment to advance ProstACT Global Phase 3 into U.S. Part 2 for TLX591-Tx in mCRPC, with safety data from Part 1 deemed sufficient. The trial will combine the therapy with abiraterone, enzalutamide, or docetaxel, pending IND amendment review.

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

Jun 23, 2026

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

New Research Advances Cancer Immunotherapy Through Clinical Data, Resistance Mechanisms, and Microbiome Insights

Jun 21, 2026

New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.

ESMO Guidelines Endorse Lutetium Therapy; New Data on PSMA Prediction, DOAC Safety

Jun 01, 2026

European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.

Ultra-Low-Dose Immunotherapy Shows Clinical Activity Across Multiple Trials

May 27, 2026

Three trials show ultra-low-dose checkpoint inhibitors retain efficacy with reduced toxicity and dramatically lower costs. DELII and Patil et al. trials tested low-dose nivolumab in solid tumors and HNSCC; NIVIPIT tested intratumoral low-dose ipilimumab in melanoma.

STAMPEDE Analysis Links Low On-Treatment PSA to Better Survival in Advanced Prostate Cancer

May 13, 2026

A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07776639	Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction	RECRUITING	PHASE2
NCT07768189	A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma	NOT_YET_RECRUITING	PHASE3
NCT07747740	Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer	RECRUITING	PHASE2
NCT07743632	Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC	NOT_YET_RECRUITING	PHASE2
NCT07730151	Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.	NOT_YET_RECRUITING	PHASE2
NCT07723248	A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)	RECRUITING	PHASE3
NCT07699757	HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion	NOT_YET_RECRUITING	PHASE1
NCT07698535	Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial	NOT_YET_RECRUITING	PHASE2
NCT07668752	A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation	RECRUITING	PHASE3
NCT07662018	Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors	RECRUITING